Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies

This study is open to adults aged 18 and over who have been diagnosed with an advanced or metastatic cancer that cannot be cured by surgery. Specifically, we are looking for people with non-uveal/non-mucosal melanoma, Merkel cell carcinoma, a specific type of kidney cancer (clear cell renal cell carcinoma or renal cell carcinoma with sarcomatoid features), or non-small cell lung cancer.

To be eligible, you must be a candidate for first or second-line immunotherapy. This means your doctor thinks immunotherapy (either alone or sometimes with other specific treatments like VEGFR-directed or tyrosine kinase inhibitor drugs for kidney cancer) is an appropriate treatment for you, and it won't include chemotherapy. Even if you have certain genetic changes like KRAS G12C mutations in lung cancer, you might still be considered.

You also need to have at least one cancer site that can be measured on scans (like CT or MRI) and hasn't been treated with radiation recently. The study team will check all your medical details carefully to make sure you meet all the necessary requirements.

The detailed involvement for this specific study isn't fully described in the provided information. However, generally, taking part in a study like this would typically involve an initial screening visit to ensure you meet all the health criteria. If eligible, you would likely have at least one PET/CT scan (and potentially other scans like CT or MRI) where you'd receive the study substance (zirconium Zr 89 crefmirlimab berdoxam) before the scan. There will also be follow-up visits and assessments to track your health and how your cancer is responding to your regular immunotherapy treatment. Total duration refers to how long researchers will follow your progress, which could range from several months to a few years, depending on the study design.